{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T21:07:08Z","timestamp":1696626428577},"reference-count":29,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001868","name":"National Science Council","doi-asserted-by":"crossref","award":["NSC 101-2314-B-002-117","NSC102-2314-B-002-067"],"award-info":[{"award-number":["NSC 101-2314-B-002-117","NSC102-2314-B-002-067"]}],"id":[{"id":"10.13039\/501100001868","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ygyno.2013.07.087","type":"journal-article","created":{"date-parts":[[2013,7,20]],"date-time":"2013-07-20T01:15:49Z","timestamp":1374282949000},"page":"135-139","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pioglitazone does not affect the risk of ovarian cancer: Analysis of a nationwide reimbursement database in Taiwan"],"prefix":"10.1016","volume":"131","author":[{"given":"Chin-Hsiao","family":"Tseng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.07.087_bb0005","doi-asserted-by":"crossref","first-page":"789174","DOI":"10.1155\/2012\/789174","article-title":"Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms","volume":"2012","author":"Arcidiacono","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0010","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1093\/jnci\/90.23.1774","article-title":"Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone","volume":"90","author":"Risch","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0015","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2011.06.016","article-title":"The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma","volume":"123","author":"King","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ygyno.2011.01.008","article-title":"Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines","volume":"121","author":"Attias-Geva","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0025","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1080\/10590501.2012.735519","article-title":"Peroxisome proliferator-activated receptor agonists and bladder cancer: lessons from animal studies","volume":"30","author":"Tseng","year":"2012","journal-title":"J Environ Sci Health C Environ Carcinog Ecotoxicol Rev"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0030","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/carcin\/bgh160","article-title":"PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis","volume":"25","author":"Nicol","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0035","first-page":"833","article-title":"Peroxisome proliferator-activated receptor alpha and gamma ligands inhibit the growth of human ovarian cancer","volume":"18","author":"Shigeto","year":"2007","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0040","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2337\/dc10-1068","article-title":"Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study","volume":"34","author":"Lewis","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0045","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0050","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes","volume":"356","author":"Nissen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0055","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2337\/dc10-1640","article-title":"Diabetes and risk of prostate cancer: A study using the National Health Insurance","volume":"34","author":"Tseng","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0060","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1007\/s00125-011-2171-z","article-title":"Diabetes and risk of bladder cancer: A study using the National Health Insurance database in Taiwan","volume":"54","author":"Tseng","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0065","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/GCO.0b013e32833e1264","article-title":"Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update","volume":"22","author":"Katsiki","year":"2010","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0070","doi-asserted-by":"crossref","first-page":"e16179","DOI":"10.1371\/journal.pone.0016179","article-title":"Specific thiazolidinediones inhibit ovarian cancer cell line proliferation and cause cell cycle arrest in a PPAR\u03b3 independent manner","volume":"6","author":"Al-Alem","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0075","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1582-4934.2009.00954.x","article-title":"Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner","volume":"15","author":"Rattan","year":"2011","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0080","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ygyno.2011.06.038","article-title":"Use of metformin and the risk of ovarian cancer: a case\u2013control analysis","volume":"123","author":"Bodmer","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0085","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/IGC.0b013e31828189b2","article-title":"Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies","volume":"23","author":"Lee","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0090","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2007.08.002","article-title":"Relationships of uterine and ovarian tumors to pre-existing chronic conditions","volume":"107","author":"Brinton","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0095","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1023\/A:1020271000069","article-title":"Diabetes mellitus and ovarian cancer (Sweden)","volume":"13","author":"Weiderpass","year":"2002","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0100","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10552-011-9794-8","article-title":"Impaired glucose metabolism and diabetes and the risk of breast, endometrial, and ovarian cancer","volume":"22","author":"Lambe","year":"2011","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0105","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1055-9965.EPI-12-0867","article-title":"Type II diabetes mellitus and the incidence of epithelial ovarian cancer in the cancer prevention study-II nutrition cohort","volume":"21","author":"Gapstur","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0110","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ygyno.2010.12.329","article-title":"The impact of diabetes on survival in women with ovarian cancer","volume":"121","author":"Bakhru","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0115","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdr534","article-title":"Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer","volume":"23","author":"He","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0120","doi-asserted-by":"crossref","first-page":"514310","DOI":"10.1155\/2010\/514310","article-title":"The role of dysregulated glucose metabolism in epithelial ovarian cancer","volume":"2010","author":"Kellenberger","year":"2010","journal-title":"J Oncol"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2407-13-94","article-title":"Sugary food and beverage consumption and epithelial ovarian cancer risk: a population-based case\u2013control study","volume":"13","author":"King","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0130","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.0001-6349.2004.00550.x","article-title":"Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies","volume":"83","author":"Riman","year":"2004","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0135","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/cncr.24126","article-title":"Glucose as a prognostic factor in ovarian carcinoma","volume":"115","author":"Lamkin","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1377\/hlthaff.22.3.61","article-title":"Taiwan's new national health insurance program: genesis and experience so far","volume":"22","author":"Cheng","year":"2003","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.ygyno.2013.07.087_bb0145","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10552-012-9946-5","article-title":"Cancer among patients with diabetes, obesity and abnormal blood lipids: a population-based register study in Sweden","volume":"23","author":"Attner","year":"2012","journal-title":"Cancer Causes Control"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581301007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581301007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T12:31:19Z","timestamp":1539520279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581301007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S009082581301007X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.07.087","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pioglitazone does not affect the risk of ovarian cancer: Analysis of a nationwide reimbursement database in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.07.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}